1,25-(OH)_2维生素D_3放射受体检测技术的建立及其在原发性骨质疏松症中的实验研究

Radioreceptor assay for 1,25 Dihydroxy vitamin D 3 in serum and its application in the study of osteoporosis

目的建立一种改良的血清１，２５－（ＯＨ）２维生素Ｄ３即１，２５二羟基胆钙甾醇（１，２５－ｄｉｈｙｄｒｏｃｈｏｌｅ－ｃａｌｃｉｆｅｒｅｌ，ＤＨＣＣ）超微量放射受体检测技术（ＲＲＡ），对原发性骨质疏松症血清的ＤＨＣＣ含量进行检测。方法用非均相核素交换法制备了３Ｈ－ＤＨＣＣ，应用超速离心技术制备胞浆受体蛋白，改进提取与纯化手段，建立ＤＨＣＣ放射受体分析方法，检测了骨质疏松症患者血样。结果完成灵敏度、精密度、准确度、稳定性及特异性等方法学技术指标，经分析检测的原发性骨质疏松症患者血清，ＤＨＣＣ含量明显低于正常老年对照组（Ｐ＜０．０５）。结论ＤＨＣＣ降低是发生骨质疏松症的重要原因之一。

Objective To establish a modified radioreceptor assay(RRA) for 1,25 (OH) 2 D 3(1,25 Dihydroxy Vitamin D 3,1,25 Dihydroxycholecalciferol DHCC) and to determine DHCC content in serum of patients with osteoporosis.Methods A hetergeneous radionuclide exchange technique was used to produce 3H DHCC.Cytoplasmic receptor protein was prepared by ultracentrifugation.Extraction and purification for DHCC were improved.RRA for DHCC was established,with which to determine DHCC content in serum of patients with osteoporosis.Results A modified RRA technique was established.which has high sensitivity,stability accuracy and specificity.DHCC content in serum of patients with osteoporosis was lower than that of the control( P <0 05).Conclusions The decrease of DHCC content might be one of the important factors for osteoporosis.